About Otogenetics Who We Are
In 2007, the advent of Next Generation Sequencing (NGS) Technology marked a pivotal moment in the realization of high throughput and precise genetic testing for multigene and complex genetic diseases. Founded by professors from Emory University School of Medicine with support from the National Institute of Health (NIH), Otogenetics emerged to pioneer the development and provision of advanced genetic testing services to research institutions and clinical care providers.
Since then, the company has developed research tools and clinical testing for esteemed Academic and Research Institutions as well as Clinical Diagnostic Laboratories in over 30 countries, counting among its US clientele institutions like the NIH, CDC, Harvard University, Stanford University, University of California San Francisco, MIT, and accredited clinical laboratories. The company is accredited by CAP, and applies NGS and other advanced technologies for molecular and genetic testing, public health survey, research, and medical education.
Pioneering Laboratories in the USA Otogenetics Comprehensive Test Offerings
As one of the pioneering laboratories in the USA, Otogenetics enrolled in CAP NGS proficiency tests early on, consistently achieving 100% accuracy.
Its comprehensive test offerings now span Single Gene and Expanded Carrier Screening, NIPT, Molecular Screening of Congenital Hearing Loss, Familial Hypercholesterolemia, Familial Hyperlipidemia, Nonsyndromic Monogenic Obesity Gene Testing, Diabetes MODY Gene Testing, Familial Early-onset Alzheimer Disease Risk Gene Testing, Hereditary Cancer Risk Assessment, clinical exome, rare diseases, and other tests tailored for personalized medicine or clinical trials.
Publications & Training Our Pivotal Role in Training and Medical Emergencies
NGS and other advanced technologies conducted by Otogenetics furnishes clinicians and researchers with genetic diagnoses and risk assessments, leading to publications in esteemed biomedical journals such as Nature and Nature Medicine, a testament to the quality and caliber of the company’s gene panel design. Moreover, Otogenetics has played a pivotal role in training a new generation of medical students in precision medicine through collaborations with medical schools.
In response to the COVID-19 pandemic in 2020, Otogenetics validated highly sensitive molecular testing for COVID-19 and collaborated with a CMO/OEM manufacturer to validate lateral flow rapid detection devices for COVID-19 IgM/IgG antibodies. Additionally, the company worked with a manufacturer to validate a COVID-19 PCR test meeting FDA standards, recognized for its high sensitivity.
In anticipating medical needs, Otogenetics developed and validated RhVISIONTM non-invasive fetal RhD typing using maternal cell-free (DNA cfDNA). The test addressed the medical urgency arising from shortages of Rho(D) immune globulin (RhIG), or known as RhoGAM, as announced by FDA.
